Evidence map›Paper›PMID 35818499›Full record

ArticlePragmatic and observational research2022

Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.

Kerry L Hancock, Sinthia Bosnic-Anticevich, John D Blakey, Mark Hew, Li Ping Chung, Biljana Cvetkovski, Scott Claxton, Peter Del Fante, Eve Denton, Joe Doan and 16 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pragmatic and observational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 4 countries.

Kerry L HancockChandlers Hill Surgery, Happy Valley, SA, 5159, Australia.
Sinthia Bosnic-AnticevichSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.ORCID 0000-0001-5077-8329
John D BlakeyRespiratory Medicine, Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, WA, 6009, Australia.
Mark HewAllergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, 3004, Australia.
Li Ping ChungFiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA, 6150, Australia.
Biljana CvetkovskiWoolcock Institute of Medical Research, Glebe, MSW, 2037, Australia.
Scott ClaxtonGenesis Care Sleep and Respiratory, Joondalup, WA, 6027, Australia.
Peter Del FanteHutt Street General Practice, Adelaide, SA, 5000, Australia.
Eve DentonAllergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, 3004, Australia.
Joe DoanHealthPlus Medical Centre, Kogarah, NSW, 2217, Australia.
Kanchanamala RanasingheSchool of Medicine, Griffith University, Nathan, QLD, Australia.
Lucy MorganSydney Medical School, University of Sydney, Sydney, NSW, Australia.
Anita SharmaPlatinum Medical Centre, Chermside, QLD, 4032, Australia.
Peter K SmithGriffith University, Southport, QLD, Australia.
Deb StewartAdjunct Lecturer, School of Medicine, University of Tasmania, Churchill Ave, Hobart, TAS, 7005, Australia.
Philip J ThompsonThe Lung Health Clinic, Hollywood Medical Centre, Nedlands, 6009, Australia.
Russell WisemanSuncoast Medical Centre, Coolum Beach, QLD, 4573, Australia.
John W UphamDiamantina Institute & PA-Southside Clinical Unit, the University of Queensland, Woolloongabba, QLD, 4102, Australia.ORCID 0000-0002-0017-3433
Kwok Y YanDepartment of Respiratory Medicine, W, Camperdown, NSW, 2050, Australia.
Victoria CarterOptimum Patient Care, Cambridgeshire, CB24 3BA, UK.
Kiranjeet DhillonOptimum Patient Care Australia, Brisbane, QLD, 4000, Australia.
Florian HeraudOptimum Patient Care Australia, Brisbane, QLD, 4000, Australia.ORCID 0000-0002-9584-1843
Thao LeOptimum Patient Care, Cambridgeshire, CB24 3BA, UK.
Rebecca VellaOptimum Patient Care Australia, Brisbane, QLD, 4000, Australia.ORCID 0000-0001-5221-3524
David PriceOptimum Patient Care, Cambridgeshire, CB24 3BA, UK.ORCID 0000-0002-9728-9992
OPCA Improving Asthma outcomes in Australia Research Group
Alfred Health · AUGriffith University · AUThe University of Sydney · AUCooperative Trials Group for Neuro-Oncology · AUCurtin University · AUFiona Stanley Hospital · AUGenesis HealthCare · USThe University of Queensland · AUThe University of Western Australia · AUUniversity of Aberdeen · GBUniversity of Tasmania · AUWoolcock Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Asthma poses a significant burden for the Australian population. Understanding severe exacerbation rates, and steroid-related burden for adults diagnosed with asthma stands to offer insights into how this could be reduced. Methods: Electronic medical records (EMR) and questionnaires from the Optimum Patient Care Research Database Australia (OPCRDA) were utilised retrospectively. OPCRDA is a real-world database with >800,000 medical records from Australian primary care practices. Outcomes were severe asthma exacerbations in Australian adults, over a 12-month period, stratified by Global Initiative for Asthma (GINA) treatment intensity steps, and steroid associated comorbidities. Results: Of the 7868 adults treated for asthma, 19% experienced at least one severe exacerbation in the last 12-months. Severe exacerbation frequency increased with treatment intensity (≥1 severe exacerbation GINA 1 13%; GINA 4 23%; GINA 5a 33% and GINA 5b 28%). Questionnaire participants reported higher rates of severe exacerbations than suggested from their EMR (32% vs 23%) especially in steps 1, 4 and 5. Patients repeatedly exposed to steroids had an increased risk of osteoporosis (OR 1.95, 95% CI 1.43-2.66) and sleep apnoea (OR 1.78, 95% CI 1.30-2.46). Conclusion: The Australian population living with GINA 1, 4, 5a and 5b asthma have high severe exacerbation rates and steroid-related burden, especially when compared to other first world countries, with these patients needing alternative strategies or possibly specialist assessment to better manage their condition.

Indexed as

adultsasthmaAustraliaexacerbationsoral corticosteroids

Identifiers

PMID35818499
PMCPMC9270906
OpenAlexW4283805826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.